Nutraceuticals for Canine Liver Disease

Assessing the Evidence


      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Veterinary Clinics: Small Animal Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Johnson S.E.
        Chronic hepatic disorders.
        in: 5th edition. Textbook of veterinary internal medicine. vol. 2. Saunders, Philadelphia2000: 1298-1325
        • Center S.A.
        Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders.
        Vet Clin North Am Small Anim Pract. 2004; 34: 67-172
        • Boothe D.M.
        Nutraceuticals in veterinary medicine, Part 1: definitions and regulations.
        Compend Contin Educ Pract Vet. 1997; 19: 1248-1255
        • Brower V.
        Nutraceuticals: poised for a healthy slice of the healthcare market?.
        Nat Biotechnol. 1998; 16: 728-731
        • Zeisel S.H.
        Regulation of “nutraceuticals.”.
        Science. 1999; 285: 185-186
        • Meyer D.J.
        • Thompson M.B.
        • Senior D.F.
        Use of ursodeoxycholic acids in a dog with chronic hepatitis: effects on serum hepatic tests and endogenous bile acid composition.
        J Vet Intern Med. 1997; 11: 195-197
        • Walter R.
        • Dunn M.E.
        • d’Anjou M.A.
        • et al.
        Nonsurgical resolution of gallbladder mucocele in two dogs.
        J Am Vet Med Assoc. 2008; 232: 1688-1693
        • Wallace K.
        • Center S.A.
        • Hickford F.
        • et al.
        S-adenosyl-L-methionine (SAMe) for the treatment of acetaminophen toxicity in a dog.
        J Am Anim Hosp Assoc. 2002; 38: 246-254
        • Vogel G.
        • Tuchweber B.
        • Trost W.
        • et al.
        Protection by silibinin against Amanita phalloides intoxication in beagles.
        Toxicol Appl Pharmacol. 1984; 73: 355-362
        • Paulova J.
        • Dvorak M.
        • Kolouch F.
        • et al.
        Verification of the hepatoprotective and therapeutic effect of silymarin in experimental liver injury with tetrachloromethane in dogs.
        Vet Med (Praha). 1990; 35: 629-635
        • Kigawa G.
        • Nakano H.
        • Kumada K.
        • et al.
        Improvement of portal flow and hepatic microcirculatory tissue flow with N-acetylcysteine in dogs with obstructive jaundice produced by bile duct ligation.
        Eur J Surg. 2000; 166: 77-84
        • Baumann J.
        • Ghosh S.
        • Szakmany T.
        • et al.
        Short-term effects of N-acetylcysteine and ischemic preconditioning in a canine model of hepatic ischemia-reperfusion injury.
        Eur Surg Res. 2008; 41: 226-230
        • Center S.A.
        • Warner K.L.
        • Erb H.N.
        Liver glutathione concentrations in dogs and cats with naturally occurring liver disease.
        Am J Vet Res. 2002; 63: 1187-1197
        • Skorupski K.A.
        • Hammond G.M.
        • Irish A.M.
        • et al.
        Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs.
        J Vet Intern Med. 2011; 25: 838-845
        • Webster C.R.
        • Cooper J.
        Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease.
        Vet Clin North Am Small Anim Pract. 2009; 39: 631-652
        • Center S.A.
        • Warner K.L.
        • McCabe J.
        • et al.
        Evaluation of the influence of S-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs.
        Am J Vet Res. 2005; 66: 330-341
        • Beuers U.
        Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
        Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 318-328
        • Paumgartner G.
        Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets.
        World J Gastroenterol. 2006; 12: 4445-4451
        • Flora K.
        • Hahn M.
        • Rosen H.
        • et al.
        Milk thistle (Silybum marianum) for the therapy of liver disease.
        Am J Gastroenterol. 1998; 93: 139-143
        • Flatland B.
        Botanicals, vitamins, and minerals and the liver: therapeutic applications and potential toxicities.
        Comp Cont Educ. 2003; 25: 514-524
        • Twedt D.C.
        A review of traditional and not so traditional therapies for liver disease.
        in: Proceedings, 19th Annual American College of Veterinary Internal Medicine Forum. American College of Veterinary Internal Medicine, Denver (CO)2001: 610-612
        • Sun N.
        • Zhang X.
        • Lu Y.
        • et al.
        In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating.
        Planta Med. 2008; 74: 126-132
        • Zafarullah M.
        • Li W.Q.
        • Sylvester J.
        • et al.
        Molecular mechanisms of N-acetylcysteine actions.
        Cell Mol Life Sci. 2003; 60: 6-20
        • Vandeweerd J.M.
        • Coisnon C.
        • Clegg P.
        • et al.
        Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis.
        J Vet Intern Med. 2012; 26: 448-456